Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...
After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...
REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Earlier this week, Revolution Medicines reported positive results from a global Phase III trial of its RAS‑targeting inhibitor daraxonrasib (RMC-6236) in metastatic pancreatic ductal adenocarcinoma ...
Italy awarded a €211 million ($249 million) grant to a company seeking to speed up processing at artificial intelligence data centers as part of a bid to support local startups. 2D Photonics Group’s ...
This is Heard on the Street writer Jonathan Weil, filling in for Spencer Jakab. Hopes are rising that diplomacy will lead to a cease-fire in the Middle East. Futures jumped, oil prices fell and ...
Behind every hyperscale data centre lies a global free market of energy, copper, and logistics that must be discussed just as much as artificial intelligence. The AI boom sweeping across the United ...
NVIDIA's DLSS 5 has proven to be one of the more controversial announcements so far this year. When initially announced, NVIDIA CEO Jensen Huang said it was using new "neural rendering" techniques and ...
TL;DR: NVIDIA's DLSS 5 processes only 2D frames and motion vectors, lacking access to 3D geometry or PBR data, causing AI to alter character details and ignore artistic intent. Despite developer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results